EXPLOITATION OF HUB PROTEINS AS DRUG TARGETS FOR MYCOBACTERIUM TUBERCULOSIS H37RV

Authors

  • ASRA’A A ABDUL-JALIL University of Anbar Collage of Science .

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i11.20662

Keywords:

Mycobacterium tuberculosis, Candidate drug targets, Interactome, Low-complexity regions

Abstract

Objective: Mycobacterium tuberculosis (TB), a causative agent of TB, increased the resistance to most drugs in use and coinfection with HIV. It needs the new drug(s), the latter should be special candidate targets.

Methods: Hub proteins were studied (Rv2198c, Rv2507, and Rv3763) which had very high connected partners. These were modeled to be used for screening chemical databases.

Results: The proteins were found to be with increased low-complexity regions especially at the amino ends, they exhibited primary level (layers) of interactions and involved in secondary and more levels of interactions.

Conclusions: The proteins with high interacting partners would be good targets as their disruption will disturb the cellular functions. The chosen targets (Rv2198c, Rv2507, and Rv3763) have very high interactions at a different level (layers), they were modeled to be used in survey of chemical databases.

Downloads

Download data is not yet available.

References

James PE, Grinberg OY, Michaels G, Swartz HM. Intraphagosomal oxygen in stimulated macrophages. J Cell Physiol 1995;163(2):241-7.

Tekaia F, Gordon SV, Garnier T, Brosch R, Barrell BG, Cole ST. Analysis of the proteome of Mycobacterium tuberculosis in silico. Tuber Lung Dis 1999;79(6):329-42.

Cui T, Zhang L, Wang X, He Z. Uncovering new signaling proteins and potential drug targets through the interactome analysis of Mycobacterium tuberculosis. BMC Genomics 2009;10:118-27.

Eisenberg D, Marcotte EM, Xenarios I, Yeates TO. Protein function in the post-genomic era. Nature 2000;405(6788):823-6.

Kanji A, Hasan R, Zaver A, Ali A, Imtiaz K, Ashraf M, et al. Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis. Int J Mycobacteriol 2016;5 Suppl 1:S97-8.

Koseki Y, Kanetaka H, Tsunosaki J, Munier-Lehmann H, Aoki S. Tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione derivatives as novel antibacterial compounds against Mycobacterium. Int J Mycobacteriol 2017;6:61-9.

Korycka-Machala M, Nowosielski M, Kuron A, Rykowski S, Olejniczak A, Hoffmann M, et al. Naphthalimides selectively inhibit the activity of bacterial, replicative DNA ligases and display bactericidal effects against tubercle bacilli. Molecules 2017;22:1-10.

Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, Berriman M, et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 2010;4(8):e804.

Newman M. The structure and function of complex networks. SIAM Rev 2003;45:167-256.

Albert R, Jeong H, Barabási A. Error and attack tolerance of complex networks. Nature 2000;406:378-82.

Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, et al. Towards a new tuberculosis drug: Pyridomycin-nature’s isoniazid. EMBO Mol Med 2012;4(10):1032-42.

Coletta A, Pinney JW, Solís DY, Marsh J, Pettifer SR, Attwood TK. Low-complexity regions within protein sequences have position-dependent roles. BMC Syst Biol 2010;4:43.

Verstrepen KJ, Jansen A, Lewitter F, Fink GR. Intragenic tandem repeats generate functional variability. Nat Genet 2005;37(9):986-90.

Ekman S, Bjorklund A, Elofsson A. What properties characterize the hub proteins of the protein-protein interaction network of the protein interaction network of Saccharomyces cerevisiae? Genome Biol 2006;7:R45.

Zhang R, Lin Y. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res 2009;37:D455-8.

Magariños MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, Shanmugam D, et al. TDR Targets: A chemogenomics resource for neglected diseases. Nucleic Acids Res 2012;40:D1118-27.

Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 1996;266:540-53.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-52.

Hu Z, Mellor J, Wu J, DeLisi C. VisANT: An online visualization and analysis tool for biological interaction data. BMC Bioinformatics 2004;5:17.

Altschul S, Madden T, Schäffer A, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-402.

Altschul SF, Wootton J, Gertz M, Agarwala R, Morgulis A, Schäffer A, et al. Protein database searches using compositionally adjusted substitution matrices. FEBS J 2005;272:5101-9.

Krogh A, Larsson B, von Heijne G, Sonnhammer E. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J Mol Biol 2001;305:567-80.

Laskowski RA. PDBsum: Summaries and analyses of PDB structures. Nucleic Acids Res 2001;29:221-2.

Schultz J, Copley RR, Doerks T, Ponting CP, Bork P. SMART: A web-based tool for the study of genetically mobile domains. Nucleic Acids Res 2000;28:231-4.

Lamichhane G, Zignol N, Blades D, Geiman A, Dougherty J, Grosset K, et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2003;100:7213-8.

Raman K. Construction and analysis of protein-protein interaction networks. Autom Exp 2010;2(1):2.

Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001;411(6833):41-2.

Raman K, Chandra N. Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance. BMC Microbiol 2008;8:234.

Wanker EE, Sun Y, Savitz AJ, Meyer DI. Functional characterization of the 180-kD ribosome receptor in vivo. J Cell Biol 1995;130(1):29-39.

Moxon ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol 1994;4(1):24-33.

Toll-Riera M, Radó-Trilla N, Martys F, Albà MM. Role of low-complexity sequences in the formation of novel protein coding sequences. Mol Biol Evol 2012;29(3):883-6.

Dyson H, Wright P. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005;6:197-208.

Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L. Activity of drugs against dormant Mycobacterium tuberculosis. Int J Mycobacteriol 2016;5 Suppl 1:S94-5.

Shaji J, Shaikh M. Drug-resistant tuberculosis: Recent approach in polymer based nanomedicine. Int J Pharm Pharm Sci 2016;8(10):1-6.

Kaithamanakallam R, Karunakaran R, Srikumar P. Anti-tuberculosis drugs against mycobacterium tuberculosis PknB and mutants L33d/D76A-a comparative docking study. Int J Pharm Pharm Sci 2014;6(1):662-4.

Published

01-11-2017

How to Cite

ABDUL-JALIL, A. A. . “EXPLOITATION OF HUB PROTEINS AS DRUG TARGETS FOR MYCOBACTERIUM TUBERCULOSIS H37RV”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 11, Nov. 2017, pp. 362-5, doi:10.22159/ajpcr.2017.v10i11.20662.

Issue

Section

Original Article(s)

Most read articles by the same author(s)